These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 25776192)

  • 21. Midostaurin approved for FLT3-mutated AML.
    Levis M
    Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML?
    Wang ES
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101103. PubMed ID: 31779982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
    Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X
    BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.
    Fiedler W; Kayser S; Kebenko M; Janning M; Krauter J; Schittenhelm M; Götze K; Weber D; Göhring G; Teleanu V; Thol F; Heuser M; Döhner K; Ganser A; Döhner H; Schlenk RF
    Br J Haematol; 2015 Jun; 169(5):694-700. PubMed ID: 25818407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report.
    Tollkuci E
    J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
    Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FLT3 inhibitors in acute myeloid leukemia: Current and future.
    Thomas CM; Campbell P
    J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia.
    Wei A; Tan P; Perruzza S; Govindaraj C; Fleming S; McManus J; Avery S; Patil S; Stevenson W; Plebanski M; Spencer A
    Br J Haematol; 2015 Apr; 169(2):199-210. PubMed ID: 25643589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
    Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
    Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
    Weis TM; Marini BL; Bixby DL; Perissinotti AJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
    Larson RA; Mandrekar SJ; Huebner LJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Voso MT; Klisovic RB; Galinsky I; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Döhner H; Stone RM
    Leukemia; 2021 Sep; 35(9):2539-2551. PubMed ID: 33654204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
    Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia.
    Medeiros BC; Tanaka TN; Balaian L; Bashey A; Guzdar A; Li H; Messer K; Ball ED
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):346-352.e5. PubMed ID: 29572158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin.
    Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G
    Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study.
    Gemuenden C; Benz R; Senn O; Goede JS; Manz MG; Gerber B
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):811-5. PubMed ID: 26437871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy.
    Ivanoff S; Gruson B; Chantepie SP; Lemasle E; Merlusca L; Harrivel V; Charbonnier A; Votte P; Royer B; Marolleau JP
    Am J Hematol; 2013 Jul; 88(7):601-5. PubMed ID: 23619977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.